NeuroSense Therapeutics Ltd. Logo

NeuroSense Therapeutics Ltd.

A late-clinical stage company developing drugs for neurodegenerative diseases like ALS.

NRSN | US

Overview

Corporate Details

ISIN(s):
IL0011809592 (+1 more)
LEI:
Country:
United States of America
Address:
11 HAMENOFIM ST., 4672562 HERZLIYA

Description

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NeuroSense Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeuroSense Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeuroSense Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELADON PHARMACEUTICALS PLC Logo
Researches, cultivates, and manufactures cannabinoid-based medicines for chronic pain.
United Kingdom
CEL
Celemics, Inc. Logo
Develops NGS target enrichment solutions for research and clinical applications.
South Korea
331920
Develops radiopharmaceuticals and radioligand therapies for oncology.
South Korea
308430
CELL BIOTECH CO ., LTD Logo
Develops and manufactures probiotic solutions using patented dual-coating technology.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based immunotherapies for severe inflammatory and allergic diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.
United States of America
CLRB
Cellectis Logo
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
France
ALCLS
Cellid Co., Ltd. Logo
Develops immunotherapeutic vaccines for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Researches and develops health foods, derma-cosmetics, and OTC pharmaceuticals.
South Korea
471820
CellSeed Inc. Logo
Develops and commercializes cell sheet engineering for regenerative medicine.
Japan
7776

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.